Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. (17/20)

Conference report: reviving pharmaceutical R&D with translational science, regulatory efficiency and innovative models. (18/20)

Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. (19/20)

Biosimilars in oncology: from development to clinical practice. (20/20)

• 1
• 2
• 3